Latest news with #COG
Associated Press
24-06-2025
- Health
- Associated Press
Children's Hospital of Philadelphia and St. Jude Researchers Find Genetic Ancestry Influences How Gene Mutations Impact Cancer Prognosis in Patients With T-cell Acute Lymphoblastic Leukemia
Study is the first to explore the impact of genetic ancestry on tumor genomics in T-ALL PHILADELPHIA and MEMPHIS, Tenn., June 24, 2025 /PRNewswire/ -- Investigators at Children's Hospital of Philadelphia (CHOP), St. Jude Children's Research Hospital (St. Jude), Dana Farber Cancer Institute (DFCI), and the Children's Oncology Group (COG), unveiled for the first time that changes in certain genes affect an aggressive cancer, T-cell acute lymphoblastic leukemia (T-ALL), differently depending on genetic ancestry. The collaborative study, published recently in the journal Blood Cancer Discovery, further reinforces the critical role of personalized medicine in advancing the treatment of pediatric cancers such as T-ALL. Most children in the U.S. newly diagnosed with cancer are treated through clinical trials or with regimens established by earlier trial findings. Increasingly, these frontline trials use prognostic biomarkers to guide treatments related to whether patients have high risk or low risk disease. While previous studies found that genetic ancestry affects how certain gene changes appear in cancer, researchers can now show that these gene changes may also predict outcomes differently depending upon an individual's ancestry. 'Our research demonstrates it is essential to ensure the equitable implementation of genomic biomarkers in treatment decisions or we may introduce disparities,' said David T. Teachey, MD, a lead study author at CHOP and Chair of the Acute Lymphoblastic Leukemia Disease Committee in the COG. 'Without this critical step, we risk misclassifying patients into the incorrect high- or low-risk groups, potentially causing undertreatment and increased risk of relapse, or overtreatment and unnecessary side effects, especially in populations of non-European descent.' Study participants were enrolled in the COG's multicenter phase 3 randomized clinical trial AALL0434 (NCT04408005) conducted from 2007 to 2014. Of the eligible participants evaluable with T-ALL, researchers analyzed complete sequencing for 1,309 individuals included in this study. They found that 80% had mutations in genes where prognostic impact varied depending on their genetic ancestry. For example, a gene called NOTCH1 was linked to better survival in patients of European ancestry but was not associated with better survival in patients of African ancestry. Importantly, this collaborative study brought together experts in the diagnosis and treatment of T-ALL, leukemia genomics, genetic ancestry and social determinants of health research, including study co-author Kira Bona, MD, MPH from DFCI. 'The study provides another important example of the way in which heritable and tumor-acquired genetic variations interact to determine the features and behavior of leukemia,' said study author Charles Mullighan, MBBS (Hons), MSc, MD, Senior Deputy Director of the St. Jude Comprehensive Cancer Center. The study evaluated tools that group patients into risk categories. One method worked well for everyone, no matter their ancestry. But another tool used, developed mainly from European data, sometimes gave misleading results for people from backgrounds other than European ancestry. The researchers also emphasized that certain genetic ancestries may be associated with more aggressive disease forms or different responses to treatment. 'Our groups have a long-standing interest in how genetic ancestry affects cancer biology in children. This study is another example of the fruitful collaboration with COG that led to the discovery of new genetic basis of racial/ethnic differences in leukemia,' said co-corresponding author Jun J. Yang, PhD, Endowed Chair in Pharmacogenomics of the St. Jude Department of Pharmacy and Pharmaceutical Sciences. 'The lessons learned from this work should be investigated in other types of cancer in children and adults to improve outcomes for patients of all ancestral backgrounds,' said first author Haley M. Newman, MD, a junior faculty member at CHOP. The research was supported by K12CA076931-24, Gabriella Miller Kids First (X01HD100702), R03CA256550, Alex's Lemonade Stand Foundation, the Leukemia and Lymphoma Society, Singapore NMRC, Singapore NUHS NCSP, Hyundai Hope on Wheels, (R01CA193776),(U10CA180886), (R01CA264837), (U24CA114766), (U24CA196173), (U10CA180899, Research Foundation, Pennsylvania Department of Health, the Harrison Willing Memorial Research Fund, The Invisible Prince Foundation, the Aiden Everett Davies Innovation Fund, ALSAC the fundraising and awareness organization of St. Jude, The St. Jude Chromatin Collaborative, (P30CA021765), (R35CA197695), (U54CA243124) and the Canadian Institute for Health Research. Newman et al. 'Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia.' Blood Cancer Discov. Online May 28, 2025. DOI: 10.1158/ About Children's Hospital of Philadelphia: A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey. CHOP also operates the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia, the Behavioral Health and Crisis Center (including a 24/7 Crisis Response Center) and the Center for Advanced Behavioral Healthcare, a mental health outpatient facility. Its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit About St. Jude Children's Research Hospital St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer, sickle cell disease and other life-threatening disorders. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 60 years ago. St. Jude shares the breakthroughs it makes to help doctors and researchers at local hospitals and cancer centers around the world improve the quality of treatment and care for even more children. To learn more, visit read St. Jude Progress a digital magazine, and follow St. Jude on social media at @stjuderesearch. Contact: Jennifer Lee Children's Hospital of Philadelphia (267) 426-6084 [email protected] Contact: Michael Sheffield St. Jude Children's Research Hospital (901) 379-6072 [email protected] [email protected] View original content: SOURCE Children's Hospital of Philadelphia
Yahoo
16-06-2025
- Business
- Yahoo
Shenango Valley Shuttle Service Launches Mobile Fare Collection Platform, RideSVSS, on June 16
In Partnership with Modeshift, New Digital System Brings Contactless Payments and Mobile QR Code Validation to Mercer County's Fixed-route Service HERMITAGE, Pa., June 16, 2025--(BUSINESS WIRE)--The Shenango Valley Shuttle Service, operated by the Mercer County Regional Council of Governments (COG), launches a new digital fare payment platform on June 16, designed to bring convenience and flexibility to riders across the Shenango Valley. The third generation fare collection system, developed in partnership with Modeshift, introduces contactless mobile payments and ticketing, allowing riders to pay and board with a tap of their smartphone. Riders can now use a free app to purchase fares and validate their trip by scanning a QR code onboard. While the mobile system marks a major step forward in transit modernization for the region, cash payments will still be accepted on all Shenango Valley Shuttle Service routes to offer riders flexible payment options. Standard one-way fares remain $1.25. A new One-Day Pass is also available for riders who plan to make multiple trips in a single day. One-Day passes must be purchased through the app or at the customer service center located at 2495 Highland Rd. Hermitage, PA. "Our goal is to ensure we're serving the needs of the Mercer County and Shenango Valley communities as they evolve," said Jill Boozer, Executive Director of the Mercer County Regional COG. "By introducing new technology, we're not only making transit more convenient but also opening the door to future improvements that reflect how people live and travel today." Key features of the new system include: Mobile App: Riders can download the app for Apple or Android devices, enabling fare payment and QR-code ride validation directly from their smartphones. The app is available now to download in both Apple and Google Play Stores: iOS: Android: One-Day Pass Option: A new pass type designed for added convenience and value for riders making multiple trips in a day. Web Portal: Riders can take advantage of RideSVSS' features through a convenient online portal that streamlines fare purchases and trip planning. Visit for more details. Smart Pay Account: Custom profiles to manage travel, view past purchases, buy passes and add funds to smart cards or digital wallets. Smart Cards: For riders who prefer not to use their phones, reloadable smart cards connected to e-wallets offer an easy, tap-and-go alternative. Data-Driven Planning: The digital platform provides real-time usage insights to help inform future service changes and improvements. "This launch is about more than just going digital, it's about laying the foundation for a transit system that's responsive, forward-looking, and easier to use," said Miroslav Katsarov, CEO of Modeshift. "Shenango Valley is joining a growing movement of agencies using modern fare collection to connect more meaningfully with the communities they serve." The new digital platform does not apply to the Mercer County Community Transit, which continues to operate separately. The shuttle currently operates four fixed routes, Monday through Friday 8:00 am- 5:00 pm, and two on Saturday 8:00 am- 4:00 pm, excluding Sundays and select holidays. To learn more about the Shenango Valley Shuttle Service partnership and other initiatives, visit About Modeshift Modeshift, Inc. is a technology company that helps transit agencies modernize their user-facing technology and the underlying infrastructure to improve efficiency, increase ridership and provide adequate, sustainability-oriented service. It is the only all-in-one digital mobility infrastructure platform that also gives the transit industry the tools to reduce their carbon emissions and aim for sustainability. Our core product is Account-based Fare Collection System, based on the Microsoft Azure cloud and delivered as a service (Software as a Service – SaaS). Modeshift also provides other subsystems which complete the stack of hardware and software needed to operate a modern transit system such as Mobile ticketing, AVL/CAD and real-time passenger information. View source version on Contacts Media Contact: Daria Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-06-2025
- General
- Yahoo
Paws of War ENC receive grant to help aid in military service dog training
NEW BERN, N.C. (WNCT) — Paws of War ENC was awarded the Military Officers of America's (MOAA) Community Outreach Grant (COG) for the third year straight. MOAA's Community Outreach Grant provides assistance to local uniformed service members, veterans, and their families to improve their quality of life. MOAA's local affiliate, Coastal Carolina, partners with the Paws of War Eastern North Carolina Program to assist veterans, active duty, and first responders in selecting, training, and certifying their dogs as companions, therapy, or service dogs. To place the right dog with the right service member, the program works closely with local shelters, law enforcement K9 units, and veterinarians. Once a dog is placed with the right service member, they will train to assist with combat injuries or other health issues, which may last up to 18 to 24 months. The grant has helped close to 100 owner/dog teams pass basic obedience training, with 30 going on to achieve American Kennel Club Canine Good Citizen Certifications, and for some State and Federal certifications as registered service dogs. For more information about Paws of War ENC and their program, please contact them at 252-330-6700. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Business Wire
03-06-2025
- Business
- Business Wire
Metropolitan Washington Council of Governments Adds 908 Devices' XplorIR to Its Hazardous Materials Response Toolkit
BOSTON--(BUSINESS WIRE)-- 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that the Metropolitan Washington Council of Governments (COG) has purchased eight XplorIR devices, one for each of the seven counties and District of Columbia, which comprise the COG. The devices were shipped in Q1 2025, with training taking place in Q2 2025. The handheld XplorIR gas analyzer from 908 Devices is a crucial addition to our hazardous materials response toolkit. The ability to quickly detect and identify an unknown gas provides the information we need to contain a potentially dangerous situation. Share The handheld XplorIR device accurately detects, identifies, and quantifies 5,000 unknown gas and vapor chemical threats in seconds. The device has simple controls, an intuitive display and is built for harsh environments, making it easy for first responders to use in emergency situations. 'The XplorIR is a crucial addition to our response toolkit,' said Peter J. Dziubla, Captain, DC Fire and EMS Department, Hazardous Materials Unit. 'The ability to quickly detect and identify an unknown gas provides the information we need to contain a potentially dangerous situation and to keep people safe.' The Metropolitan Washington COG is an independent, nonprofit association that brings District of Columbia, Maryland and Virginia leaders together to address regional issues, such as homeland security and public safety. COG brings police chiefs, fire chiefs, emergency managers, and other leaders together to strengthen regional public safety coordination, homeland security planning, and emergency communication. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company's devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in vital health and safety applications, such as the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit Forward Looking Statements for 908 Devices This press release includes "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company's products. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management's current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under "Risk Factors" and elsewhere in the Company's filings with the Securities and Exchange Commission which are available on the SEC's website at Additional information will be made available in the Company's annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
&w=3840&q=100)
Business Standard
22-05-2025
- Business
- Business Standard
SAIL's Bhilai plant installs new system to cut emissions, boost efficiency
Safety and monitoring systems have been deployed for safe and efficient COG operations, said BSP officials Raipur SAIL 's Bhilai Steel Plant (BSP) has achieved a milestone in its targets for energy efficiency and emissions by commissioning a Coke Oven Gas (COG) Injection System, said a statement. The system will use coke oven gas, which has 'significant calorific value', as an auxiliary fuel in producing sinter, a mass of fine iron ore dust and other materials fused together as part of steelmaking. According to the BSP officials, injecting COG into a sinter bed reduces around 2 kg of coke per tonne of sinter produced. It improves sinter quality and cuts carbon emissions by an estimated 12,700
